ClinicalTrials.gg

Program

HRS-4357

A development code. Also written as “HRS-4357 injection”.

In Jiangsu HengRui Medicine's pipeline, PSMA. Its studies are mostly in Prostatic Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Dec 16, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine22 open or runningphase 3since Dec 16, 2025Aug 8, 2023Dec 2027phase 3 · NCT07311694
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-4357, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2023First study: phase 2 study in Advanced Prostate CancerFirst studyNCT06006104 · 49 planned
  2. Dec 16, 2025Phase 3 study in PSMA-Positive Progressive Metastatic Castration-Resistant Prostate CancerPhase 3 reachedNCT07311694 · 370 planned · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in PSMA-Positive Progressive Metastatic Castration-Resistant Prostate CancerNCT07311694

TargetBeta

“PSMA”the company's pipeline, read by Claude · source

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07311694PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer · China3RecruitingDec 2027370
NCT06006104Advanced Prostate Cancer2Not yet recruitingSep 30, 202449

How it is read

Names in the registry

  • “HRS-4357 injection”, 2 entries

Codes read as this program: HRS4357.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.